Bristol Myers Squibb Announces Updated Data From TRIDENT-1 Trial Show Durable Efficacy Benefits With Repotrectinib For Patients With Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Portfolio Pulse from Happy Mohamed
Bristol Myers Squibb (NYSE:BMY) has announced updated results from the TRIDENT-1 study, showing that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), continues to show high response rates and durable responses in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration has accepted the New Drug Application for repotrectinib and granted Priority Review. The data from the trial is expected to be presented at the IASLC 2023 World Conference on Lung Cancer.
August 16, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's repotrectinib has shown promising results in the TRIDENT-1 study for treating ROS1-positive NSCLC. The FDA has accepted the New Drug Application for repotrectinib and granted it Priority Review, which could potentially lead to faster approval and market entry.
The positive results from the TRIDENT-1 study and the FDA's Priority Review status for repotrectinib are significant developments for Bristol Myers Squibb. If approved, repotrectinib could become a new standard of care for patients with ROS1-positive NSCLC, potentially leading to increased revenues for the company. This could have a positive impact on BMY's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100